CD274 and neoplasm: Moreover, we showed that sdAb K2 has therapeutic potential as it exhibits an IC50 of 8.5 nM to block PD-1:PD-L1 interactions and releases the break on antigen-specific TCR signaling and on tumor killing activity in vitro.